Stocks-ZYNE-Zynerba Pharmaceuticals Inc

ZYNE Zynerba Pharmaceuticals Inc

1.27 -0.01 (-0.39%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Stocks-ZYNE-Zynerba Pharmaceuticals Inc
ZYNE Zynerba Pharmaceuticals Inc
Trade

Zynerba Pharmaceuticals Inc price

0% Past Week
Market Cap
68.77M
Day’s Range
1.23
-
1.26
52W Range
0.2800
-
1.37
Volume (3M)
984.35K
Price-Earnings Ratio
-1.59
Revenue
-

Zynerba Pharmaceuticals Inc Latest News

View All
Zynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023Zynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023Finanz Nachrichten2 days agoHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealBusiness Journals4 days agoHarmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba PharmaceuticalsHarmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba PharmaceuticalsGreen Stock News5 days ago
Top Discussions

About Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc. is a specialty pharmaceuticals company engaged in the development of next-generation synthetic cannabinoid therapeutics for transdermal delivery. The firm was founded in 2007 and is headquartered in Devon, Pennsylvania. Zynerba has a focus on meeting the needs of patients living with a range of chronic conditions with significant unmet medical needs, including those living with rare diseases and neuropsychiatric disorders. This firm is dedicated to finding solutions for patients with neuropsychiatric conditions including Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD) and certain refractory epilepsies, by modulating neurological pathways in the central nervous system. In addition, the firm focuses on the treatment of rare diseases, 50% of which affect children, and 95% of which do not have a current FDA approved drug treatment. The company’s experimental treatment Zygel is the first and so-far only pharmaceutically produced CBD formulated as a patent-protected gel for transdermal delivery. The therapy is being developed for patients suffering from FXS, ASD in paediatric patients, and a group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE). The firm is listed on the NASDAQ under the stock ticker ZYNE. Monitor the Zynerba share price by adding ZYNE stock to your eToro watchlist today.
Armando Anido, MBA
CEO
27
Employees
2007
Founded
Devon, Pennsylvania, US
HQ
Show More
Med TechNASDAQ

Analyst Forecast

Consensus
Hold
Price Target
1.11
Based on 1 analysts who covered ZYNE 

ESG: A New Source of Insight

What is an ESG Score?
This number is a measure of a company’s exposure to environmental, social, and governance risks. Influencing factors include energy efficiency, safety, social policies, and more. Learn More
Powered by ESG Book
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
39
Very Low
Industry 
Avg. 47 
31
Environment
41
Social
53
Governance

People Also Bought